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Cytotoxic T Cells
Mads Hald Andersen1, David Schrama2, Per thor Straten1 and Jürgen C. Becker2
The immune system is a complex arrangement of cells and molecules that preserve the integrity of the organism 
by elimination of all elements judged dangerous. Within the immune system, a humoral and a cellular as well as 
an innate and an adaptive arm can be differentiated. The key players of adaptive cellular immune responses are 
T lymphocytes in general and, for the effector function, cytotoxic T lymphocytes (CTLs) in particular. T lympho-
cytes arise in the bone marrow and migrate to the thymus for maturation. During this process, T cells somatically 
rearrange gene segments, eventually leading to the expression of a unique antigen-binding molecule, the T-cell 
receptor (TCR). This receptor allows them to monitor all cells of the body, ready to destroy any cell posing a threat 
to the organism. Cytotoxicity is exerted directly through the Fas or perforin pathway and/or indirectly by the 
release of cytokines. Obviously, the activity of such a potent cell is tightly regulated. Indeed, a predominance of 
stimulatory over inhibitory signals is required for effective immune responses to pathogens, and a predominance 
of inhibitory over stimulatory signals is required for maintenance of self-tolerance. Still, several situations occur in 
which an inappropriate CTL response leads to either autoimmune disease or persistence of pathogens.
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The immune system is a remark-
ably adaptive defense system that has 
evolved in vertebrates, protecting the 
host against invading pathogenic micro-
organisms. This is achieved in a dynamic 
network of an enormous variety of cells 
and molecules capable of specifically 
recognizing and eliminating a large vari-
ety of antigens. Once a pathogen has 
been recognized, the immune system 
enlists the participation of a variety of 
cells and molecules to mount an appro-
priate response to eliminate or neutral-
ize the threat. Subsequent exposure to 
the same pathogen induces a memory 
response, characterized by a more rapid 
and heightened immune reaction.
Immunity includes both nonspecific 
and specific components. The nonspe-
cific component, innate immunity, rep-
resents a set of resistance mechanisms 
against infection that are not specific to 
a particular pathogen. In contrast, the 
specific component, adaptive immu-
nity, displays a high degree of specific-
ity as well as the remarkable property 
of memory. Because the initiation of 
an adaptive immune response requires 
some time, innate immunity provides 
the first line of defense during the criti-
cal period just after the host’s exposure 
to a pathogen. Innate immunity and 
adaptive immunity do not operate inde-
pendently of each other but rather work 
together to elicit an effective immune 
responses. For example, the action 
of phagocytes can generate “danger” 
signals that stimulate and direct the 
adaptive immune responses, and it can 
display the phagocytosed antigen in a 
manner that allows it to be recognized 
by antigen-specific T cells. Likewise, 
after encountering appropriately pre-
sented antigen, some T cells synthesize 
and secrete cytokines that may activate 
macrophages, increasing their ability to 
kill ingested microbes, a function of the 
innate immune response.
The adaptive immune system con-
sists of a cellular and a humoral 
branch. The former is largely mediated 
by T cells, the latter by B cells. Both 
cell types arise from the bone marrow. 
However, unlike B cells, T cells migrate 
to the thymus for maturation. Still, even 
when matured T lymphocytes leave the 
thymus, they are considered naive cells 
until exposed to antigen in a suitable 
context. After maturation in the thymus, 
the T cell expresses a unique cell sur-
face antigen-binding molecule called 
the T cell receptor (TCR). This antigen-
binding molecule consists of two trans-
membrane molecules, the TCR-α and 
the TCR-β, that are the result of rear-
rangement of first the TCR-β and then 
the TCR-α gene. In contrast to mem-
brane-bound antibodies on B cells, 
which can recognize antigen alone, the 
vast majority of TCRs recognize a com-
plex ligand that includes an antigenic 
peptide bound to a major histocompat-
ibility complex (MHC)-derived mol-
ecules (Moss et al., 1992) (Figure 1a). 
The MHC is a cluster of genes arrayed 
within a longitudinal stretch of DNA on 
chromosome 6 in humans and chromo-
some 17 in mice, the product of which 
plays a central role in intercellular rec-
ognition and discrimination between 
self and non-self. Two major forms of 
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these polymorphic membrane-bound 
glycoproteins exist, MHC class I and 
class II molecules. Class I and class II 
molecules interact with different co-
receptors on the T cells, that is, CD8 
and CD4, respectively. Whereas class 
I molecules are expressed by nearly all 
nucleated cells, class II molecules are 
constitutively expressed only by anti-
gen-presenting cells (APCs); however, 
they can be induced in the majority of 
cells, in particular by IFN-γ.
In general, mature T lymphocytes 
express either CD4 or CD8 molecules, 
hence allowing for identification of 
CD4+ T helper (Th) cells and CD8+ 
cytotoxic T lymphocytes (CTLs). Th 
cells produce cytokines required for 
triggering of the humoral and the cell-
mediated immune response. In this 
regard, activation of Th cells is care-
fully regulated, and naive CD4+ cells 
become activated only upon encoun-
tering antigen presented by HLA class 
II complexes in the context of appro-
priate co-stimulatory molecules on the 
surface of professional APCs such as 
dendritic cells (DCs) (Stockwin et al., 
2000) (Figure 1b). Moreover, their dif-
ferentiation is actively regulated by a 
small but highly potent sub-population 
of T cells. These regulatory T cells have 
recently received much attention for 
their role in prevention of autoimmu-
nity (see Beissert et al., this issue). The 
role of the CD8+ T cells is to monitor all 
the cells of the body, ready to destroy 
any that is considered to be a threat to 
the integrity of the host; for example, 
CTLs kill virally infected cells, prevent-
ing them from being the source of more 
viral pathogen.
Moreover, CTLs are also thought 
to provide some degree of protec-
tion against spontaneous malignant 
tumors, by virtue of their ability to 
detect quantitative and qualitative 
antigenic differences in transformed 
cells. In this regard, transformation 
results in an altered protein repertoire 
inside the cell. CD8+ T cells recognize 
antigen that is presented by MHC class 
I-derived molecules that sample pep-
tides from protein degradation inside 
the cell and present these at the cell 
surface to CTLs; this enables CTLs 
to scan for cellular alterations (Castelli 
et al., 2000).
The aim of this review is to provide 
an overview of CTLs and their func-
tion in physiological and pathological 
situations. Functionally, an immune 
response can be divided into two relat-
ed activities, recognition and response. 
Consequently, we first describe how T 
cells recognize their targets and how 
they become activated. The next sec-
tion describes T cell-mediated cytotox-
icity. This is followed by a description 
of the markers that help to identify the 
different types and activation states of 
T cells. Finally, we try to outline how 
an understanding of CTL biology may 
be translated into the clinical situation. 
CTLs have an impact on a wide variety 
of clinical situations, such as autoim-
munity allergic reactions and infectious 
and neoplastic diseases. However, 
the largest body of evidence has been 
obtained over the years in the field of 
tumor immunology; thus, we focus the 
clinical part of the review on this field.
TCR-Mediated Recognition of Target Cells
In 1996, Zinkernagel and Doherty were 
awarded the Nobel Prize in Medicine 
for demonstrating that CD8+ T cells 
could only recognize virally infected 
target cells if they expressed a particu-
lar set of MHC molecules (Zinkernagel, 
1997). In humans, all nucleated cells 
express up to six different class I mol-
ecules, which are encoded on chromo-
some 6 in the MHC locus; the human 
MHC is referred to as HLA complex and 
contains three loci (HLA-A, -B, and -C). 
The MHC molecules are able to present 
a vast range of peptides. It is estimated 
that there are up to 250,000 of each 
HLA class I molecule on the surface of 
a cell (Parham and Ohta, 1996).
The expression of mature, peptide-
loaded class I molecules at the cell 
surface requires coordination of three 
essential processes: first, the protea-
somal degradation of endogenous pro-
teins to peptides in the cytosol; second, 
the translocation of peptides across the 
endoplasmic reticulum membrane; 
and third, the assembly of the MHC 
heavy chain with the antigenic peptide 
and the associated molecule β2 micro-
globulin, and the transport of the latter 
to the cell surface (Figure 2a). In addi-
tion to this classical MHC class I path-
way in which the antigens presented 
are of intracellular origin, processing 
of exogenous antigens for presenta-
tion by MHC class I molecules is now a 
widely recognized alternative pathway 
(Reimann and Kaufmann, 1997). This 
pathway, which is probably restricted 
to APCs, is termed the alternative MHC 
class I pathway, or cross-presentation 
(Figure 2b). In this pathway, profession-
al APCs such as DCs, which are essen-
tial for the induction of CTL responses, 
internalize exogenous antigens by 
endocytosis and present fragments of 
these antigens in the context of MHC 
molecules to various effector cells 
of the immune system. It is generally 
assumed that endocytosed antigens, 
either before or after processing, may 
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Figure 1. Peptide presentation and T-cell 
activation. The TCR recognizes antigenic 
peptides presented in the context of major 
histocompatibility complex (MHC) (a). TCR-
mediated recognition of a peptide antigen bound 
to an MHC-derived molecule represents a central 
event for cellular immune responses. Cytotoxic 
T lymphocytes (CTLs) can destroy any cell that 
expresses the respective peptide/MHC class I 
complex. As HLA class I complexes are present 
on most nucleated cells, activation of CTLs is 
carefully regulated; that is, CD4+ cells produce 
cytokines required for triggering of CTL response. 
For CD4+ T helper (Th) cells, the TCR reacts with 
peptides presented by MHC class II, which have 
a more restricted expression pattern. Moreover, 
upon TCR triggering, naive Th cells become 
activated only in the presence of a co-stimulatory 
signal mediated, for example, by B7 and CD28 
present on the surface of professional antigen-
presenting cells (APCs) such as dendritic cells (b).
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exit the endosomal pathway into the 
cytosol, where they can enter the clas-
sical MHC class I presentation pathway 
(Wilson and Villadangos, 2005); direct 
evidence proving this notion, however, 
still remains elusive.
TCR-mediated recognition of a pep-
tide antigen bound to an MHC-derived 
molecule represents a central event for 
cellular immune responses. The TCR 
contacts the MHC complex through the 
TCR variable domains (Garboczi et al., 
1996). The affinity between TCR and 
peptide/MHC is orders of magnitude 
weaker than that of comparable anti-
body–antigen interactions. However, 
because the MHC molecules serve not 
only as ligands for the TCR, but also 
as non-antigen-specific ligands for the 
TCR co-receptors — for example, class 
I molecules for CD8 and class II mole-
cules for CD4 — even these weak inter-
actions are sufficient to initiate signal 
transduction in CTLs. Indeed, in CTLs 
the CD8 molecule has two functions as 
a receptor, both recognizing the ligand 
and initiating signal transduction. As is 
outlined in the following section, CD4 
and CD8, however, are not the only co-
receptors that are important in the acti-
vation of CD8+ CTLs.
A single TCR can recognize a vari-
ety of peptide/MHC ligands. Agonist 
ligands are peptide/MHC complex-
es that induce complete TCR signal 
transduction, resulting in widespread 
changes in gene expression. Antagonist 
ligands inhibit responses induced by 
the agonist. In addition, a subset of 
ligands are inhibitory for multiple cellu-
lar responses, such as proliferation and 
cytokine production, but at the same 
time induce some alterations in gene 
expression and functional response in 
T cells. Indeed, they induce a subset 
of the responses triggered by agonist 
ligands and therefore have been named 
partial agonists. Partial-agonist signal-
ing can lead to cellular responses that 
are qualitatively different from those 
induced by agonist signaling. For exam-
ple, naive T cells proliferate and differ-
entiate in response to agonist, whereas 
partial-agonist signals lead to survival 
without significant proliferation or dif-
ferentiation. In this respect the TCR is 
unique, as different cellular responses 
are determined by signaling through a 
single receptor that interprets subtle dif-
ferences in ligand structure.
Co-Stimulatory Signals and Cytotoxic T-
Lymphocyte Activation
Crucial elements of cellular immune 
responses are the activation, clonal 
expansion and differentiation of T cells. 
The signal transduction events dur-
ing activation of CTLs and Th cells are 
generally similar. In addition, activation 
of either population of T cells is not an 
independent process but may largely 
be influenced by the other. Activation 
of CTLs can be divided into two phas-
es, reflecting different aspects of the 
response. The first phase activates naive 
T cells and differentiates them into 
functional effector cells; in the second 
phase, these effector cells recognize 
antigen on specific target cells, which 
results in the destruction of the target 
cell (see “Killing of Target Cells” below).
T-cell activation is a complicated 
process that includes mobilization 
of Ca2+, new transcription, release of 
preprocessed and retained surface 
receptors, internalization of surface 
receptors, altered susceptibility to 
apoptosis, and the release of granules 
(containing perforin and so on).
At different stages of differentiation, 
T cells may respond with different effi-
ciencies to signals mediated by the 
TCR and may therefore require differ-
ent levels of co-stimulatory signals for 
activation. For example, activation of 
naive T cells and their subsequent dif-
ferentiation into effector cells require 
the primary signal via the TCR and 
CD4 or CD8 co-receptors and co-stim-
ulatory signals. In contrast, antigen-
experienced cells are able to respond 
to TCR-mediated signals with little, if 
any, co-stimulation. These differences 
are at least in part due to the expres-
sion of distinct isoforms of CD45, that 
is, CD45RA and CD45RO (see also “
T-Cell Markers” below). These isoforms 
are generated by alternative splicing of 
the mRNA transcript, and the result-
ing proteins exert a phosphatase activ-
ity that catalyzes dephosphorylation 
of the protein tyrosine kinases Lck and 
Fyn (Figure 3), which activates these 
kinases and triggers subsequent steps 
of T-cell activation. Notably, CD45RO, 
expressed on memory T cells, exhibits 
Figure 2. MHC class I antigen processing and antigen presentation pathways. In general, MHC class 
I-presented peptides are derived from intracellular proteins (a). These are degraded by the proteasome 
and transported through the transporter associated with antigen processing (TAP) in the endoplasmic 
reticulum. There, newly synthesized MHC class I molecules are stabilized by calnexin until β2 
microglobulin binds to the complex. The partial folded MHC class I complex binds to the TAP complex, 
and, after binding of peptide, the peptide/MHC complex is transported through the Golgi apparatus to 
the cell surface. Alternatively, exogenous proteins are phagocytosed, and endocytosed antigens may 
exit the endosomal pathway into the cytosol, either before or after processing, where they can enter 
the classical MHC class I presentation pathway (b). These proteins are retro-transported out of the 
endoplasmic reticulum and degraded by the proteasome. The degraded peptides can now enter the 
normal pathway through the TAP complex.
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stronger association with the TCR and 
its co-receptors than CD45RA, improv-
ing the efficiency of the TCR signaling. 
Additionally, the nature of the epitope 
also influences the outcome of TCR-
mediated signaling. Complete peptide 
agonists stimulate the cell to perform 
all of these functions. Partial-agonist 
peptides are defined as ligands that 
induce a measurable T-cell response 
while inducing minimal proliferation 
or no proliferation. Many models of 
T-cell activation have been proposed 
to explain the differential effects of 
altered peptides. These models include 
changes in the kinetics of signal trans-
duction, formation of the immunologi-
cal synapse, induction of a negative 
signal and recruitment of TCR or co-
stimulatory molecules. In addition, the 
induction of cytolysis without stimula-
tion of T-cell proliferation can also be 
triggered by peptides with decreased 
affinity for MHC; this highlights the 
interaction between peptide and MHC 
as an important factor in determin-
ing the outcome of TCR engagement. 
Thus, it should be noted that peptide 
antagonists not only compete for bind-
ing to MHC class I molecules but also 
alter the cascade of processes that 
result in T-cell activation (Kilgore et al., 
2004) (Figure 3). Generation of effector 
CTLs appears to require at least three 
sequential signals: (1) TCR ligation; 
(2) co-stimulatory signals transmitted, 
for example, by CD28–B7 interac-
tions; and (3) IL-2-mediated signaling. 
Unactivated naive CD8+ T cells do not 
express IL-2 or its receptors, which are 
induced only upon TCR- and CD28-
mediated signaling. The amount of 
IL-2 production induced by these sig-
nals, however, may not be sufficient to 
ensure full activation. In such cases, 
activated Th cells may provide addi-
tional IL-2.
The best-characterized co-stimula-
tory signaling system required for the 
activation of naive T cells is based on 
the interaction of B7 with CD28 and 
CTL-associated antigen 4 (CTLA-4) 
(Figure 1b) (Greenwald et al., 2005). 
Nevertheless, this pathway is rather 
complex because of the dual specific-
ity of B7-1 (CD80) and B7-2 (CD86) for 
the stimulatory receptor CD28 and the 
inhibitory receptor CTLA-4 (CD152). 
B7–CD28 binding delivers signals 
important for activation of naive T cells, 
whereas CTLA-4 inhibits T-cell respons-
es and regulates peripheral T-cell toler-
ance. CD28 is constitutively expressed 
on the surface of T cells, whereas 
CTLA-4 expression is rapidly upregu-
lated after T-cell activation. CTLA-4 has 
a higher affinity for both B7-1 and B7-
2 than does CD28. The expression of 
other CD28 family members, for exam-
ple, ICOS, can also be induced on T 
cells, and they have important roles in 
regulating previously activated T cells. 
Thus, CD28 and ICOS synergize to pro-
mote the activation of T-cell responses, 
with CD28 having a predominant role 
during initial T-cell activation and ICOS 
regulating memory T cells. Importantly, 
B7–CD28 interactions have a critical 
role in the homeostasis of CD4+CD25+ 
regulatory T cells, which regulate self-
tolerance and T-cell activation (Lohr et 
al., 2003; Beissert et al., this issue). In 
addition, recent studies demonstrate 
that after engagement of CTLA-4, B7 
can transmit suppressive signals into 
DCs by reverse signaling (Greenwald et 
al., 2005).
Signaling through CD28 molecules 
reduces the number of TCR–peptide/
MHC interactions necessary for T-cell 
activation; in addition, other mem-
brane-bound or soluble molecules 
modulate the activation of T cells, 
either by direct signaling or by increas-
ing the affinity of cell-to-cell interac-
tion. The expression of MHC class I 
on the cell surface of the APC and the 
expression of a relevant cytokine by the 
APC may also facilitate CTL activation. 
Th cells have also been shown to play 
an important role in the generation of 
CTLs. In 1998, it was shown that signal-
ing through the CD40 that is expressed 
on mature DCs is the prime means of 
Th cell-dependent preparation of APCs 
for CTL generation. Schoenberger and 
colleagues demonstrated that priming 
of CTL responses against a tumor anti-
gen critically depended on this CD40 
signaling (Schoenberger et al., 1998). 
This CD40-mediated signaling of APCs, 
however, did not require a cognate 
T-cell interaction but could be substi-
tuted by crosslinking of CD40 with an 
antibody. Similarly, Matzinger’s group 
demonstrated that DCs treated in vitro 
with an anti-CD40 mAb could be used 
to prime the Th cell-dependent CTL 
response to the H-Y antigen in mice 
deficient in Th cells (Ridge et al., 1998). 
Further characterization of the effect of 
CD40 signaling on DCs revealed the 
downstream events necessary for APC 
licensing. For example, IL-12, a strong 
amplifier of CTL responses, is induced 
by CD40 ligation (O’Sullivan and 
Thomas, 2003). Similarly, the expres-
sion of the co-stimulatory 4-1BB ligand 
on activated T cells is a consequence of 
CD40 signaling (Laderach et al., 2003).
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Figure 3. Full and partial T-cell activation. TCR ligation by immunogenic peptides leads to 
phosphorylation (closed circles) of all immunoreceptor tyrosine-based activation motifs (ITAMs) of 
the CD3 complex, recruitment, and/or activation of the src kinases and thus full T-cell activation (a). 
Altered peptide ligand engagement causes incomplete phosphorylation of CD3 ITAMs (open circles) and 
ineffective recruitment of src kinases (b). Red circles represent phosphorylation sites. Therefore, some 
SH2 domain-containing proteins may not be able to bind to the signaling complex.
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In summary, activation of CTLs is a 
result of binding of TCR to antigen, sig-
naling through a variety of co-stimulatory 
molecules on the T cell, and signals gen-
erated from APCs and Th cells. The effi-
ciency of CTL activation is due in large 
part to the nature of the TCR stimulation 
as well as the co-stimulatory signal.
T-Cell Markers
As is outlined above, activation of CTLs 
results not only in proliferation but also 
in differentiation of the activated cell. 
To this end, circulating CD8+ T cells 
can be divided into four groups, naive, 
effector, effector/memory, and memory 
cells, each of which represents a dis-
tinct activation/differentiation status 
of a given T-cell clone. These different 
states of T-cell activation are associated 
with distinct functional and phenotypic 
characteristics (Figure 4). For example, 
naive T cells circulate only between the 
peripheral blood and lymphatic tissues, 
whereas some of the antigen-experi-
enced sub-populations are able to enter 
other tissues. Furthermore, effector T 
cells express high levels of perforin, 
have strong cytolytic activity and pro-
duce low levels of cytokines such as 
IL-2 and IFN-γ, whereas effector/mem-
ory cells display medium levels of per-
forin, allowing only a limited cytotoxic 
activity, but produce high levels of cyto-
kines (Tomiyama et al., 2002) (Figure 4). 
In contrast, memory CD8+ T cells fail to 
kill target cells but can proliferate and 
produce cytokines in response to anti-
gen stimulation (Kaech et al., 2002).
In addition to functional character-
ization, there are cell surface markers 
that have proven helpful in the clas-
sification of the different T-cell popu-
lations (Figure 4). Thus, a phenotypic 
classification of human CD8+ T cells 
using the co-stimulatory receptors 
CD27 and CD28 as well as CD45RA 
or CD45RO has been validated as 
useful for the distinction of naive, 
memory, and effector CD8+ T cells 
(Tomiyama et al., 2002). In this regard, 
naive CD8+ T cells express CD27, 
CD28, and CD45RA, whereas memory 
cells lose the expression of CD45RA. 
Effector CD8+ T cells are CD27–CD28–
CD45RA+, and effector/memory cells 
have a CD27–CD28–CD45RA– pheno-
type (Sobao et al., 2001). This notion 
has been substantiated by in situ stud-
ies scrutinizing the phenotype of indi-
vidual T-cell clones present in either 
the draining lymph node of cutaneous 
melanoma or the tumor itself (Becker et 
al., 2000). In addition, it was recently 
suggested that CD27+CD28–CD45RA–
CD8+ T cells are effector/memory cells 
as well, as they have cytotoxic activity 
and can effectively produce cytokines 
(Tomiyama et al., 2002).
The chemokine receptor CCR7 is 
a particularly useful marker for dis-
criminating naive and memory CD8+ 
T cells from effector/memory and 
effector CD8+ T cells (Champagne et 
al., 2001). CCR7 functions as a hom-
ing receptor to lymphoid tissue and 
is expressed on naive CD8+ T cells 
and a subset of memory CD8+ T cells. 
Thus, naive (CCR7+CD45RA+), cen-
tral/memory (CCR7+CD45RA–) and 
effector/memory (CCR7–CD45RA+/–) 
cells can be distinguished (Tomiyama 
et al., 2004).
It has been suggested that CD8+ cells 
switch from naive to memory status in 
response to antigen exposure and then 
gradually transform into an effector 
type (reviewed by van Baarle et al., 
2002) (Figure 4). The effector pheno-
type is CD45RAhighCD27–CD28–CCR7– 
and expresses high amounts of perfo-
rin, IFN-γ and granzyme. Furthermore, 
it has been shown that the majority 
of circulating immunization-induced 
CD8+ T cells display an intermediate 
effector/memory CD45RAhighCD27– 
phenotype. These cells are capable of 
expressing IFN-γ but demonstrate little 
or no expression of perforin. Notably, 
CD27 and perforin expression can be 
re-induced by in vitro sensitization 
associated with increased cytoplasmic 
size and significantly decreased fre-
quency of CD45RAhigh cells (Monsurro 
et al., 2002). These tumor antigen-spe-
cific CD8+ T cells possess neither a 
distinct memory nor a distinct effector 
phenotype (Monsurro et al., 2002), as 
full effector functions can be regained 
only when appropriate conditions are 
provided in vitro, for example as pre-
viously described for antigen recall 
in the presence of IL-2 (Kammula et 
al., 1999). Thus, it is possible that 
the transient status of quiescence of 
immunization-induced T cells can be 
overturned by the administration of 
cytokines such as IL-2. In fact, both 
systemic administration and tumor-tar-
geted enrichment of IL-2 significantly 
improved therapeutic vaccinations 
with tumor peptide-pulsed DCs (Eggert 
et al., 2002; Schrama et al., 2004). The 
improvement of the therapeutic effect 
can be ascribed to the ability of IL-2 
to boost preexisting immune response, 
probably by reversing the quiescent 
state of tumor-specific T cells (thor 
Straten et al., 1998).
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Figure 4. T-cell differentiation. CD8 T cells can be distinguished by the expression of different molecules such as CD45RA, CD45RO, CD28, CD27, or CCR7, 
or mediators of cytotoxicity such as IFN-γ, granzyme (Gr) or perforin.
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Killing of Target Cells
CTLs may kill target cells by one 
of at least three distinct pathways. 
Two involve direct cell–cell contacts 
between effector and target cells. The 
third is mediated by cytokines, such 
as IFN-γ and tumor necrosis factor-
α, which are produced and secreted 
as long as TCR stimulation continues 
(Figure 5a). These cytokines affect the 
opposed target cell or cells distal to the 
effector T cell. Tumor necrosis factor-α 
engages its receptor on the target cell 
and triggers the caspase cascade, lead-
ing to target-cell apoptosis. IFN-γ, how-
ever, induces transcriptional activation 
of the MHC class I antigen presentation 
pathway and Fas in target cells, leading 
to enhanced presentation of endog-
enous peptides by MHC class I, and 
increases Fas-mediated target-cell lysis. 
Cytolytic activity requiring direct cell–
cell contact, which results in apoptosis 
of target cells, can be mediated by two 
different mechanisms. In one case, the 
Fas ligand, which is expressed on the 
surface of CTLs, binds to the Fas recep-
tor (Fas, CD95) on the target cell (Figure 
5b). This binding triggers apoptosis 
through the classical caspase cascade 
(Nagata, 1996). In the other case, the 
CTL releases perforin and granzymes 
into the intercellular space (Figure 5c). 
These proteins are highly cytotoxic, 
and the CTLs have devised an elabo-
rate mechanism to protect themselves 
and neighboring cells from being killed 
accidentally while still ensuring that 
the cell can show a rapid and efficient 
cytotoxic response upon triggering the 
TCR. Firstly, the majority of the cyto-
toxic proteins are pre-synthesized, 
and so ready to be used in killing upon 
encountering a target cell. The regu-
lated secretory organelles in which the 
lytic proteins are stored mobilize them-
selves to the cell surface and expose 
their content only upon contact with a 
target. CTLs use their lysosomes as the 
regulated secretory organelles, which 
are therefore often referred to as secre-
tory lysosomes (Blott and Griffiths, 
2002). Secondly, the secretory lyso-
somes do not exocytose their content 
randomly over the cell surface but are 
mobilized to a defined point on the 
plasma membrane that is immediately 
opposite the target cell, termed the 
secretory domain. Thirdly, the secretory 
lysosomes release their content not into 
the general extracellular milieu, from 
where they could diffuse and kill other 
innocent neighboring bystander cells, 
but into a defined space, or “cleft,” that 
forms between the otherwise tightly 
opposed CTL and target-cell mem-
branes. This modus operandi therefore 
both concentrates the cytotoxic pro-
teins for maximum impact and confines 
them to the environment of the target 
cell. The uptake of the granular material 
by the target cell causes cell death in 
a caspase-dependent and -independent 
manner (Trapani and Smyth, 2002).
Cytotoxic T Lymphocytes and Disease: 
Type IV Hypersensitivity
Allergic contact dermatitis is a delayed-
type hypersensitivity reaction mediated 
by hapten-specific T cells (De Panfilis, 
1998). During the sensitization phases, 
both CD4+ and CD8+ T-cell precursors 
are activated in the draining lymph 
nodes by presentation of haptenated 
peptides. Re-challenge with the hap-
ten induces the recruitment of T cells at 
the site of challenge, that is, the skin; 
this induces inflammatory signals and 
apoptosis of epidermal cells, leading 
to the development of a skin inflamma-
tory infiltrate and to clinical symptoms 
(Girolomoni, 2004). The respective 
roles of CD4+ and CD8+ T cells in the 
development of the inflammatory reac-
tion are still the subject of controver-
sial discussions (Cavani, 2005; Saint-
Mezard et al., 2004). Experimental 
evidence, however, suggests that in 
contact hypersensitivity responses to 
strong haptens, CD8+ T cells are the 
key effector cells, whereas CD4+ T cells 
are endowed with downregulatory 
functions. Ongoing studies will have 
to confirm that the pathophysiology of 
human allergic contact dermatitis is 
indeed comparable to the murine con-
tact hypersensitivity.
Cytotoxic T Lymphocytes and Disease: 
Autoimmunity
Organ-specific autoimmune diseases 
are caused by an immune response 
directed to a target antigen unique to 
a single organ; thus, manifestations are 
largely limited to that organ. Such auto-
immune diseases may involve direct 
cellular damage mediated by anti-
bodies and/or CTLs. For example, in 
Hashimoto’s thyroiditis, both antibodies 
and T cells are involved (Brazillet et al., 
1999; Farzati et al., 2005). In insulin-
dependent diabetes mellitus and multi-
ple sclerosis, the etiological function of 
CTLs is well established (Neumann et 
al., 2002). Furthermore, recent reports 
suggest a function of CTLs in the patho-
genesis of skin diseases such as sys-
temic sclerosis and paraneoplastic 
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Figure 5. CTL-mediated cytotoxicity. (a) Indirect 
killing of target cells by release of tumor necrosis 
factor-α and IFN-γ. (b) Induction of apoptosis in 
target cells via death receptor triggering. (c) Direct 
killing by release of granzyme B and perforin into 
the intercellular space between CTL and target 
cell. TNF, tumor necrosis factor; TNFR, tumor 
necrosis factor receptor; IFNR, IFN receptor; 
Fas-L, Fas ligand.
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pemphigus (Hoffman et al., 2003; 
Tamby et al., 2003). However, the 
strongest and most direct evidence for a 
key role of CTLs in the pathogenesis of 
autoimmune disease exists for vitiligo. 
Vitiligo is a common hypopigmentary 
disorder that affects approximately 2% 
of the world population (Hartmann et 
al., 2004). The loss of skin pigmentation 
is caused by the selective destruction of 
melanocytes. The initiation and the ulti-
mate pathway of melanocytic destruc-
tion in vitiligo are, however, not fully 
understood. Observations of vitiligo 
accompanying metastatic melanoma 
(melanoma-associated hypopigmen-
tation) support a role of autoreactive 
CTLs recognizing shared melanocyte 
differentiation antigens (Becker et al., 
1999; Pedersen et al., 2002; Steitz et 
al., 2004).
Cytotoxic T Lymphocytes and Disease: 
Tumors
The largest body of evidence that CTLs 
are involved in the clinical course of 
disease exists for neoplastic disease. 
Most of the work focuses on the func-
tion of CTLs in the control (or lack of 
control) of tumors. In 1982, Van Pel 
and Boon demonstrated the genera-
tion of a protective immune response 
against an otherwise non-immuno-
genic murine tumor. This was the first 
experimental evidence that lack of 
immunogenicity of a tumor is due to 
the tumor’s inability to activate the 
immune system rather than to the 
absence of tumor antigens (Van Pel 
and Boon, 1982). Since then it has 
become clear that CD8+ CTLs alone 
or sometimes in combination with 
CD4+ Th cells constitute the effector 
arm of the adaptive immune response 
to cancer (Castelli et al., 2000). Thus, 
it is not surprising that much effort is 
spent on identification and character-
ization of tumor antigens for use in 
active immune therapy. To this end, 
the number of known T-cell epitopes 
derived from tumor-associated anti-
gens exceeds 200 and is still increasing 
(Novellino et al., 2004). The proteins 
from which these peptide antigens are 
derived can be divided into different 
groups. It should be noted, however, 
that the distinctions between some of 
the groups are somewhat arbitrary.
Group I. A number of patient-spe-
cific antigens have arisen as a result of 
somatic mutations in normal gene prod-
ucts. These antigens can be expressed 
by single tumors only (unique) or 
shared among tumors of the same entity 
(reviewed by Renkvist et al., 2001).
Group II. Group II consists of tumor-
specific antigens that nevertheless are 
shared among cancer patients. These 
antigens can be further divided into 
two subgroups. One subgroup con-
sists of viral antigens present in several 
cancers, such as Epstein-Barr virus in 
lymphoma and human papilloma virus 
in cervical cancer (Boon and van der 
Bruggen, 1996). The other subgroup 
consists of antigens that have arisen as a 
result of mutations related to the onco-
genic process and therefore are pres-
ent in a large proportion of patients. 
These antigens are mutated proteins, 
such as p53 (Ciernik et al., 1996), ras 
(Bergmann-Leitner et al., 1998), and 
bcr/abl (Yotnda et al., 1998). For this 
subgroup we recently described spon-
taneous CTL responses to the onco-
genic V600EBRaf mutation in melanoma 
patients, resulting in a selective out-
growth of melanoma cells lacking this 
mutation (Andersen et al., 2004).
Group III. The largest number of anti-
gens identified so far are shared tumor 
antigens that correspond to normal tis-
sue-specific gene products, also called 
differentiation antigens. Such antigens 
have been isolated from melanoma and 
are also expressed by normal melano-
cytes. They include MART-1/Melan A, 
gp100 and tyrosinase (Castelli et al., 
2000; Van den Eynde and Boon, 1997).
Group IV. This group of antigens con-
sists of normal proteins that are pre-
dominantly expressed by tumors 
whereas they are not present in nor-
mal tissue, with the exception of testis. 
Prototypes of this group are the MAGE, 
GAGE, and BAGE families (Boon and 
van der Bruggen, 1996; Boel et al., 
1995; Van den Eynde and Boon, 1997). 
A number of such antigens are overex-
pressed only in particular cancers, for 
example, the HER-2/neu oncogene, 
which is frequently overexpressed in 
adenocarcinomas of breast, ovary, and 
colorectum. Recently, a number of 
antigens were identified that are not 
restricted to a subgroup of tumors but 
are expressed in most if not all of the 
common human malignancies. For 
example, Vonderheide et al. demon-
strated human CTL responses against 
telomerase, a protein necessary to avoid 
replicative senescence of cancer cells 
(Vonderheide et al., 1999). Likewise, 
T-cell responses against the antiapoptot-
ic protein survivin have been described 
(Schmitz et al., 2000; Andersen et al., 
2001a; Andersen et al., 2001b).
Based on the observation that tumors 
are immunogenic, but that the induced 
immune responses are not capable of 
controlling clinically evident lesions, a 
large research effort has been launched 
to boost antitumor immune responses. 
In this regard, the T-cell growth factor 
IL-2 is being used to treat patients with 
renal-cell carcinoma and melanoma. 
Although response rates have been min-
ute, some patients have experienced 
durable responses (Atkins et al., 1999). 
This has set the stage for additional 
efforts in immune therapy of cancer, 
including the use of defined peptides 
in the specific targeting of cancer cells, 
for example, therapeutic vaccination. 
Indeed, several immunotherapeutic 
trials have been initiated for treatment 
of various malignancies, for instance, 
melanoma, cancers of the breast, pros-
tate and kidney, and hematological 
neoplasms. By various strategies it has 
now been established that it is feasible 
and safe to induce anticancer CTLs 
in patients by means of antigen-spe-
cific vaccination (Wang et al., 2001). 
Notably, although the antigens used for 
specific vaccination often belong to the 
class of differentiation antigens, which 
are also expressed by all melanocytes, 
widespread vitiligo is a rare event in 
vaccinated melanoma patients. In con-
trast, melanoma-associated hypopig-
mentation is rather frequently observed. 
A possible mechanism preventing gen-
eralized vitiligo relies on MHC-spe-
cific killer-inhibitory receptors. In this 
regard, we previously demonstrated the 
expression of activating and inhibitory 
receptors of CD94/NKG2 on T cells 
within the tumor, whereas T cells in 
the vitiligo-like leukoderma expressed 
exclusively the inhibitory isoforms 
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(Pedersen et al., 2002). Nevertheless, 
the potential targets of tumor-specific T 
cells have to possess specific features in 
order to be destroyed by the T cells. In 
accordance, in mice, DCs consistently 
trigger autoimmune responses, which, 
however, lead to clinical autoimmunity 
only in susceptible animals (Bondanza 
et al., 2003).
In general, two different vaccination 
strategies are being pursued: the use 
of vaccines that utilize whole tumor 
cells, and the use of vaccines that target 
defined antigens (Melief et al., 2000). 
Although the main components of cell-
based vaccines are irrelevant proteins, 
these vaccines hold the advantage that 
all relevant tumor antigens are cov-
ered. However, the complexity of the 
antigenic composition of tumor cells 
implies that immunological monitor-
ing of these therapeutic interventions is 
troublesome. In contrast, vaccines com-
prising defined antigens allow systemat-
ic biological monitoring, thus enabling 
immediate improvement of vaccine 
design based on the findings. However, 
the clinical effect of these defined vac-
cines has so far been marginal at best. 
Likewise, the appropriate delivery of 
tumor antigens in anticancer vaccines 
is currently under intense investigation. 
This includes DC-based vaccines or 
molecularly defined adjuvants; inflam-
matory cytokines; agents that modulate 
APC and T-cell function; and DNA-
based versus virus-based vaccine vec-
tors (Melief et al., 2000). Nevertheless, 
many questions still have to be 
answered before immunotherapy may 
represent a curative means of treatment 
of metastatic cancers; hence, it is man-
datory to scrutinize vaccine-induced 
immune responses carefully, to set the 
stage for development of more efficient 
next-generation anticancer vaccines.
Cytotoxic T Lymphocytes and Disease: 
Monitoring Immune Responses
For any treatment of cancer, the desir-
able end point is tumor regression. 
However, considering that most 
patients enrolled in immune therapeu-
tic trials are at a progressed stage of dis-
ease, objective clinical end points are 
not really expected — and rarely seen. 
Consequently, immunological moni-
toring over the course of treatment is a 
crucial step to improve our understand-
ing of antitumor immune responses. 
The methodological advances over the 
past few years, including the use of 
enzyme-linked immunospot (ELISPOT) 
(Herr et al., 1996; Keilholz et al., 2002), 
fluorescently labeled multimeric pep-
tide/MHC reagents in multicolor flow 
cytometry (Betts et al., 2003; Altman et 
al., 1996), and TCR clonotype mapping 
(Pannetier et al., 1995; thor Straten et 
al., 2001; Schrama et al., 2002a), have 
made it possible to conduct detailed 
studies to characterize the impact of 
immune modulation. In this respect, 
lack of correspondence between immu-
nological and clinical responses repre-
sents a critical concern (Schrama et al., 
2001). Indeed, tumor-specific CTLs may 
be present in the circulation in cancer 
patients despite tumor progression, and 
vice versa (Parmiani et al., 2002).
Following the characterization of 
peptide antigens recognized by autol-
ogous T cells on the surface of can-
cer cells, numerous small therapeutic 
vaccination trials against cancer have 
been performed, aiming at the induc-
tion of clinically relevant antitumor 
CTL responses. Although some reports 
have demonstrated impressive clinical 
responses (Rosenberg et al., 1998), in 
most cases vaccination has not yet con-
vincingly demonstrated any impact on 
the course of the disease (Parmiani et 
al., 2003). Hence, the increased insight 
into events induced by immune modu-
lation relies on biological monitoring. 
To this end, an improved understand-
ing of the cells and molecules that gov-
ern the success or failure of any given 
therapy may lead the way to significant 
improvements of current therapeutic 
strategies. Consequently, characteriza-
tion and tracking of the TCRs utilized 
by tumor-specific T cells may reveal 
important information as to the biology 
of antitumor T-cell responses (Andersen 
et al., 2001b; Schrama et al., 2002b; 
Schrama et al., 2003). The character-
ization of systemic tumor antigen-spe-
cific T-cell responses alone does not 
necessarily reflect their localization 
and function within the target tissue, 
the tumor site. Monitoring of antitumor 
immune responses is largely restricted 
to circulating lymphocytes, because 
this is the most convenient tissue to 
work with — and in the majority of 
cases the only tissue accessible. It is 
obvious that important information may 
be obtained from combined analyses of 
peripheral blood and tumor tissue, in 
particular because we and others have 
presented data suggesting a functional 
dissociation between local and sys-
temic immune responses (Lee et al., 
1998; thor Straten et al., 1999). In this 
respect, it may seem optimal to analyze 
the target tissue if possible. However, 
biopsies are not easily accessible, and 
frequent and/or serial sampling of biop-
sies is associated with severe discom-
fort to the patients, in particular when 
sampling goes beyond skin metastases. 
In addition, it should be kept in mind 
that differences between systemic and 
localized immune responses most like-
ly coexist with dissimilarities between 
different localized lesions in the same 
patient (thor Straten et al., 1999). This 
notion is exemplified by the com-
mon finding that some lesions regress 
whereas others progress in melanoma 
patients receiving immune therapy. 
Consequently, combinations of the out-
lined methods, applied to analyze both 
blood and tissue for characterization 
of antitumor CTL responses, may pro-
vide the necessary information. Thus, 
the use of recombinant HLA molecules 
for isolation and subsequent tracking 
of peptide-specific clonotypic T cells 
represents a strong tool to delineate the 
correlation between the in situ and the 
in sanguis situation.
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